C3orf62
gene geneOn this page
Also known as FLJ43654MAPS
Summary
C3orf62 (chromosome 3 open reading frame 62, HGNC:24771) is a protein-coding gene on chromosome 3p21.31, encoding Uncharacterized protein C3orf62 (Q6ZUJ4). Essential for normal spermatogenesis and male fertility.
Predicted to be involved in spermatogenesis.
Source: NCBI Gene 375341 — RefSeq curated summary.
At a glance
- GWAS associations: 10
- Clinical variants (ClinVar): 7 total
- MANE Select transcript:
NM_198562
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:24771 |
| Approved symbol | C3orf62 |
| Name | chromosome 3 open reading frame 62 |
| Location | 3p21.31 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | FLJ43654, MAPS |
| Ensembl gene | ENSG00000188315 |
| Ensembl biotype | protein_coding |
| Entrez | 375341 |
Gene structure
Transcript identifiers
Ensembl transcripts: 4 — 2 protein_coding, 1 nonsense_mediated_decay, 1 retained_intron
ENST00000343010, ENST00000424960, ENST00000436325, ENST00000479673
RefSeq mRNA: 1 — MANE Select: NM_198562
NM_198562
CCDS: CCDS2792
Canonical transcript exons
ENST00000343010 — 3 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001379253 | 49276427 | 49277232 |
| ENSE00001837165 | 49268596 | 49271445 |
| ENSE00003568894 | 49274049 | 49274140 |
Expression profiles
Bgee: expression breadth ubiquitous, 183 present calls, max score 86.22.
FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1787 / max 51.4237, expressed in 58 samples.
FANTOM5 promoters (4 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 42230 | 0.0742 | 15 |
| 42231 | 0.0421 | 11 |
| 42229 | 0.0312 | 8 |
| 42232 | 0.0312 | 13 |
Top tissues by expression
244 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| left testis | UBERON:0004533 | 86.22 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 86.07 | gold quality |
| right testis | UBERON:0004534 | 85.88 | gold quality |
| blood | UBERON:0000178 | 85.57 | gold quality |
| testis | UBERON:0000473 | 84.35 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 84.09 | gold quality |
| right adrenal gland | UBERON:0001233 | 83.17 | gold quality |
| granulocyte | CL:0000094 | 83.07 | gold quality |
| left ovary | UBERON:0002119 | 82.92 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 82.52 | gold quality |
| right ovary | UBERON:0002118 | 82.29 | gold quality |
| left adrenal gland | UBERON:0001234 | 81.91 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 81.72 | gold quality |
| leukocyte | CL:0000738 | 81.67 | gold quality |
| monocyte | CL:0000576 | 81.64 | gold quality |
| apex of heart | UBERON:0002098 | 81.57 | gold quality |
| adrenal cortex | UBERON:0001235 | 80.51 | gold quality |
| lower esophagus | UBERON:0013473 | 80.18 | gold quality |
| lower esophagus muscularis layer | UBERON:0035833 | 80.17 | gold quality |
| adrenal gland | UBERON:0002369 | 80.16 | gold quality |
| left uterine tube | UBERON:0001303 | 80.04 | gold quality |
| spleen | UBERON:0002106 | 79.36 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 79.19 | gold quality |
| cerebellar cortex | UBERON:0002129 | 79.15 | gold quality |
| esophagogastric junction muscularis propria | UBERON:0035841 | 78.80 | gold quality |
| omental fat pad | UBERON:0010414 | 78.62 | gold quality |
| peritoneum | UBERON:0002358 | 78.56 | gold quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 78.53 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 78.50 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 78.26 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 3.45 |
| E-MTAB-5061 | no | 2.00 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
84 targeting C3orf62, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-4795-3P | 100.00 | 74.62 | 4024 |
| HSA-MIR-3613-3P | 100.00 | 76.36 | 7965 |
| HSA-MIR-3162-3P | 100.00 | 65.37 | 363 |
| HSA-MIR-4682 | 100.00 | 68.89 | 1258 |
| HSA-MIR-607 | 99.97 | 73.62 | 5593 |
| HSA-MIR-6778-3P | 99.96 | 67.29 | 2693 |
| HSA-MIR-6753-3P | 99.93 | 66.57 | 637 |
| HSA-MIR-7107-3P | 99.93 | 66.73 | 627 |
| HSA-MIR-6809-3P | 99.91 | 71.45 | 3814 |
| HSA-MIR-4753-3P | 99.90 | 71.03 | 3786 |
| HSA-MIR-4496 | 99.88 | 68.89 | 2236 |
| HSA-MIR-3133 | 99.81 | 70.92 | 3506 |
| HSA-MIR-204-5P | 99.79 | 71.62 | 2439 |
| HSA-MIR-211-5P | 99.79 | 71.65 | 2440 |
| HSA-MIR-4319 | 99.76 | 69.83 | 2586 |
| HSA-MIR-3934-3P | 99.76 | 65.51 | 1351 |
| HSA-MIR-3913-3P | 99.74 | 66.53 | 938 |
| HSA-MIR-1976 | 99.74 | 65.48 | 1127 |
| HSA-MIR-4524A-3P | 99.72 | 66.85 | 2406 |
| HSA-MIR-494-3P | 99.70 | 71.45 | 2795 |
| HSA-MIR-12124 | 99.68 | 69.17 | 2700 |
| HSA-MIR-6848-3P | 99.64 | 66.49 | 885 |
| HSA-MIR-6134 | 99.63 | 65.68 | 1537 |
| HSA-MIR-4261 | 99.59 | 70.30 | 3415 |
| HSA-MIR-4328 | 99.57 | 71.06 | 4094 |
| HSA-MIR-6832-3P | 99.52 | 70.44 | 1726 |
| HSA-MIR-4441 | 99.49 | 66.56 | 3216 |
| HSA-MIR-122B-5P | 99.46 | 70.81 | 1457 |
| HSA-MIR-147B-5P | 99.45 | 70.62 | 2432 |
| HSA-MIR-330-3P | 99.41 | 69.95 | 2521 |
Cross-species orthologs
2 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | 1700102P08Rik | ENSMUSG00000032611 |
| rattus_norvegicus | C8h3orf62 | ENSRNOG00000046155 |
Protein
Protein identifiers
Uncharacterized protein C3orf62 — Q6ZUJ4 (reviewed: Q6ZUJ4)
All UniProt accessions (3): C9JW57, H7BZX3, Q6ZUJ4
UniProt curated annotations — full annotation on UniProt →
Function. Essential for normal spermatogenesis and male fertility.
Tissue specificity. Testis. Down-regulated in men with spermatocyte arrest.
RefSeq proteins (1): NP_940964* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR031670 | DUF4712 | Family |
Pfam: PF15830
UniProt features (5 total): modified residue 2, chain 1, sequence variant 1, sequence conflict 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q6ZUJ4-F1 | 63.49 | 0.17 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (2): 210, 224
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 56 (showing top):
IVANOVA_HEMATOPOIESIS_MATURE_CELL, GOBP_MALE_GAMETE_GENERATION, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, OSMAN_BLADDER_CANCER_DN, TGGAAA_NFAT_Q4_01, SREBP1_Q6, HATADA_METHYLATED_IN_LUNG_CANCER_UP, MIKKELSEN_MEF_HCP_WITH_H3_UNMETHYLATED, WHITFIELD_CELL_CYCLE_M_G1, BRUINS_UVC_RESPONSE_EARLY_LATE, PKCA_DN.V1_UP, SREBP_Q3, chr3p21, GSE14415_NATURAL_TREG_VS_FOXP3_KO_NATURAL_TREG_DN, ZNF22_TARGET_GENES
GO Biological Process (2): spermatogenesis (GO:0007283), cell differentiation (GO:0030154)
GO Molecular Function (1): protein binding (GO:0005515)
GO Cellular Component (0):
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| developmental process involved in reproduction | 1 |
| male gamete generation | 1 |
| cellular developmental process | 1 |
| binding | 1 |
Protein interactions and networks
STRING
308 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| C3orf62 | ANKRD65 | E5RJM6 | 479 |
| C3orf62 | KNCN | A6PVL3 | 477 |
| C3orf62 | MANSC1 | Q9H8J5 | 452 |
| C3orf62 | ZNF570 | Q96NI8 | 447 |
| C3orf62 | SUSD6 | Q92537 | 445 |
| C3orf62 | OR52B6 | Q8NGF0 | 434 |
| C3orf62 | CCDC183 | Q5T5S1 | 431 |
| C3orf62 | LSMEM1 | Q8N8F7 | 419 |
| C3orf62 | TSEN34 | Q9BSV6 | 409 |
| C3orf62 | RNF24 | Q9Y225 | 403 |
| C3orf62 | CDHR4 | A6H8M9 | 399 |
| C3orf62 | TEX9 | Q8N6V9 | 398 |
| C3orf62 | TMCC3 | Q9ULS5 | 396 |
| C3orf62 | PLPPR2 | Q96GM1 | 394 |
| C3orf62 | ROPN1L | Q96C74 | 383 |
IntAct
46 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| HAUS1 | C3orf62 | psi-mi:“MI:0915”(physical association) | 0.670 |
| MRFAP1L1 | C3orf62 | psi-mi:“MI:0915”(physical association) | 0.670 |
| C3orf62 | HAUS1 | psi-mi:“MI:0915”(physical association) | 0.670 |
| C3orf62 | EP300 | psi-mi:“MI:2364”(proximity) | 0.670 |
| C3orf62 | TXNDC9 | psi-mi:“MI:0915”(physical association) | 0.560 |
| C3orf62 | ING5 | psi-mi:“MI:0915”(physical association) | 0.560 |
| C3orf62 | MRFAP1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ING5 | C3orf62 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MRFAP1 | C3orf62 | psi-mi:“MI:0915”(physical association) | 0.560 |
| KRT3 | C3orf62 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RFPL3 | C3orf62 | psi-mi:“MI:0915”(physical association) | 0.560 |
| BFSP2 | C3orf62 | psi-mi:“MI:0915”(physical association) | 0.560 |
| C3orf62 | LMNTD2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| C3orf62 | SPRED1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| C3orf62 | RB1 | psi-mi:“MI:0914”(association) | 0.530 |
| DGCR6 | C3orf62 | psi-mi:“MI:0915”(physical association) | 0.370 |
| C3orf62 | ALDH1L1 | psi-mi:“MI:0914”(association) | 0.350 |
| C3orf62 | SCO1 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (43): C3orf62 (Two-hybrid), C3orf62 (Two-hybrid), C3orf62 (Two-hybrid), C3orf62 (Two-hybrid), C3orf62 (Two-hybrid), CREBBP (Affinity Capture-MS), EP300 (Affinity Capture-MS), RB1 (Affinity Capture-MS), RBL1 (Affinity Capture-MS), C3orf62 (Two-hybrid), EP300 (Affinity Capture-MS), CREBBP (Affinity Capture-MS), RBL1 (Affinity Capture-MS), RB1 (Affinity Capture-MS), C3orf62 (Two-hybrid)
ESM2 similar proteins: A0A0B4J1W7, A0A1B0GUC4, A4GZ95, A6NHN6, A6NJ64, A6ZT44, A8MTZ7, E9PJ23, E9PJI5, E9PKD4, E9PQR5, F8W1W9, F8WFD2, O75200, O91083, P04605, P05909, P05910, P05911, P0DM63, P0DXC3, P12453, P12513, P17759, P18044, P18098, P19507, P20880, P38839, P38900, Q02838, Q1KN10, Q1KN16, Q1KN23, Q1X6Y7, Q1X6Z0, Q1X6Z2, Q1X6Z3, Q2YDP6, Q32LJ5
Diamond homologs: Q6ZUJ4, Q9D9C7
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
7 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 2 |
| Likely benign | 0 |
| Benign | 1 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
548 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 3:49271447:T:C | acceptor_gain | 1.0000 |
| 3:49274150:CCAGG:C | acceptor_gain | 1.0000 |
| 3:49274151:C:T | acceptor_gain | 1.0000 |
| 3:49274151:CAGG:C | acceptor_gain | 1.0000 |
| 3:49274152:A:T | acceptor_gain | 1.0000 |
| 3:49271446:C:CC | acceptor_gain | 0.9900 |
| 3:49271447:T:TC | acceptor_gain | 0.9900 |
| 3:49274154:G:C | acceptor_gain | 0.9900 |
| 3:49274154:G:GC | acceptor_gain | 0.9900 |
| 3:49271442:TGGT:T | acceptor_gain | 0.9800 |
| 3:49274138:TTC:T | acceptor_gain | 0.9800 |
| 3:49271443:GGTC:G | acceptor_loss | 0.9600 |
| 3:49271444:GTC:G | acceptor_loss | 0.9600 |
| 3:49271445:TCT:T | acceptor_loss | 0.9600 |
| 3:49271446:CTTAA:C | acceptor_loss | 0.9600 |
| 3:49274136:CTTTC:C | acceptor_gain | 0.9600 |
| 3:49277173:T:TA | donor_gain | 0.9600 |
| 3:49271443:GGT:G | acceptor_gain | 0.9500 |
| 3:49271444:GT:G | acceptor_gain | 0.9500 |
| 3:49271444:GTCTT:G | acceptor_gain | 0.9500 |
| 3:49271453:A:C | acceptor_loss | 0.9500 |
| 3:49274048:CCAAT:C | donor_gain | 0.9500 |
| 3:49274139:TC:T | acceptor_gain | 0.9500 |
| 3:49274140:CC:C | acceptor_gain | 0.9500 |
| 3:49274141:C:CC | acceptor_gain | 0.9400 |
| 3:49274139:TCCTG:T | acceptor_loss | 0.9300 |
| 3:49274140:CCTGC:C | acceptor_loss | 0.9300 |
| 3:49274142:T:A | acceptor_loss | 0.9300 |
| 3:49274040:TGTAC:T | donor_loss | 0.9200 |
| 3:49274041:GTAC:G | donor_loss | 0.9200 |
AlphaMissense
1778 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 3:49276802:A:G | L24P | 0.995 |
| 3:49276794:C:G | A27P | 0.992 |
| 3:49271238:A:T | V249D | 0.991 |
| 3:49276810:T:A | R21S | 0.990 |
| 3:49276810:T:G | R21S | 0.990 |
| 3:49276811:C:A | R21I | 0.986 |
| 3:49276811:C:G | R21T | 0.986 |
| 3:49276784:C:G | R30P | 0.984 |
| 3:49276802:A:T | L24Q | 0.984 |
| 3:49276823:A:G | L17P | 0.984 |
| 3:49276790:A:T | I28N | 0.982 |
| 3:49276797:C:G | A26P | 0.980 |
| 3:49271235:A:G | L250P | 0.978 |
| 3:49276793:G:T | A27D | 0.978 |
| 3:49276782:C:G | A31P | 0.973 |
| 3:49276815:A:G | C20R | 0.973 |
| 3:49276834:C:A | M13I | 0.972 |
| 3:49276834:C:G | M13I | 0.972 |
| 3:49276834:C:T | M13I | 0.972 |
| 3:49276790:A:C | I28S | 0.969 |
| 3:49271415:A:G | L190S | 0.964 |
| 3:49276832:G:A | S14F | 0.963 |
| 3:49276781:G:T | A31D | 0.961 |
| 3:49276802:A:C | L24R | 0.961 |
| 3:49276812:T:C | R21G | 0.961 |
| 3:49276813:G:C | C20W | 0.961 |
| 3:49271225:T:A | E253D | 0.960 |
| 3:49271225:T:G | E253D | 0.960 |
| 3:49271229:A:G | L252S | 0.955 |
| 3:49276823:A:T | L17Q | 0.955 |
dbSNP variants (sampled 300 via entrez): RS1000050116 (3:49275429 T>G), RS1000222645 (3:49275693 G>A), RS1000272501 (3:49268174 C>T), RS1000403796 (3:49275720 C>CA), RS1000759051 (3:49274555 C>G,T), RS1001009254 (3:49274054 A>G), RS1001226706 (3:49276937 C>T), RS1001332877 (3:49276355 G>A), RS1001466873 (3:49276652 G>T), RS1001560603 (3:49274901 C>T), RS1002053755 (3:49274534 TA>T), RS1002658381 (3:49273169 A>C,G), RS1003017178 (3:49273432 A>G), RS1003337175 (3:49278688 GCT>G), RS1003536083 (3:49271693 G>C,T)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
10 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST004131_23 | Inflammatory bowel disease | 1.000000e-33 |
| GCST004132_17 | Crohn’s disease | 3.000000e-23 |
| GCST004133_11 | Ulcerative colitis | 8.000000e-20 |
| GCST004621_57 | Red cell distribution width | 9.000000e-10 |
| GCST010698_80 | Subcortical volume (min-P) | 3.000000e-24 |
| GCST010699_110 | Brain morphology (min-P) | 4.000000e-08 |
| GCST010701_52 | Cortical surface area (MOSTest) | 1.000000e-16 |
| GCST010702_36 | Subcortical volume (MOSTest) | 1.000000e-10 |
| GCST010703_262 | Brain morphology (MOSTest) | 2.000000e-13 |
| GCST012355_28 | Depression | 2.000000e-14 |
EFO canonical traits (2, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0009188 | Red cell distribution width |
| EFO:0004346 | neuroimaging measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
24 total (human), top 24 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Ozone | affects expression, increases abundance, decreases expression | 2 |
| Valproic Acid | affects cotreatment, increases expression, decreases expression | 2 |
| aristolochic acid I | increases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| bisphenol A | decreases methylation | 1 |
| sodium arsenite | decreases expression | 1 |
| butyraldehyde | decreases expression | 1 |
| 2-palmitoylglycerol | increases expression | 1 |
| Resveratrol | affects cotreatment, increases expression | 1 |
| Decitabine | decreases expression, affects reaction | 1 |
| Air Pollutants | affects expression, increases abundance | 1 |
| Benzo(a)pyrene | affects methylation, increases methylation | 1 |
| Demecolcine | increases expression | 1 |
| Diethylhexyl Phthalate | decreases expression | 1 |
| Doxorubicin | decreases expression | 1 |
| Ethyl Methanesulfonate | increases expression | 1 |
| Hydralazine | affects cotreatment, increases expression | 1 |
| Methyl Methanesulfonate | increases expression | 1 |
| Plant Extracts | affects cotreatment, increases expression | 1 |
| Rotenone | decreases expression | 1 |
| Tobacco Smoke Pollution | increases expression | 1 |
| Aflatoxin B1 | increases expression | 1 |
| Lactic Acid | decreases expression | 1 |
| Acrylamide | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.